Ovarian Neoplasms

The grounding supports hereditary predisposition as an important cause for a subset of ovarian cancers. Pathogenic or likely pathogenic variants in BRCA1/2 and other high-penetrance cancer susceptibility genes are associated with increased ovarian cancer risk, and genetic testing is used to identify these inherited causes. No other specific causes are supported by the supplied material.

The literature grounding supports distinct biology across ovarian tumor types, with epithelial ovarian cancer being the main focus. Co-studied mechanisms include altered gene expression regulation, DNA methylation, DNA copy number variations, signal transduction, apoptosis, drug resistance, and tumor microenvironment effects. Immune features such as tumor-infiltrating lymphocytes and checkpoint-related markers are also covered, indicating that host immune response is relevant to tumor behavior and prognosis.

Inherited pathogenic variants associated with hereditary cancer syndromes increase risk, especially BRCA1/2 variants and other high-penetrance genes discussed in NCCN guidance. The supplied abstracts also identify Ashkenazi Jewish ancestry as a group for which genetic testing criteria are specifically addressed. No additional risk factors are supported by the grounding.

For epithelial ovarian cancer, surgical cytoreduction to no gross residual disease is described as the mainstay of treatment, followed by adjuvant chemotherapy. The co-studied drug classes and agents indicate platinum-based chemotherapy, paclitaxel, and other systemic therapies, with maintenance therapy also part of management. Genetic testing is standard of care for women with epithelial ovarian cancer because results can affect systemic therapy decisions, and recurrent disease may be treated with additional modalities including targeted and immunotherapy-related approaches.